Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the company’s GLP-1 revenue stream. With Tirzepatide now officially the FDA’s shortage list, it is more likely than not that Semaglutide is removed in the next 12 months, the analyst tells investors in a research note. Citi says that if this were to happen, Hims & Hers’ weight loss market would be “significantly constrained” as it would only be able to compound GLP-1s by changing the formulation for the specific clinical benefit of an individual. As such, the firm’s GLP-1 revenue estimate falls from $400M in fiscal 2025 to $135M. Additionally, the space has become more competitive from the likes of large pharma, contends Citi.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers downgraded to Sell from Neutral at Citi
- Hims and Hers Health put volume heavy and directionally bearish
- Hims & Hers initiated with a Buy at BTIG
- Hims & Hers price target raised to $24 from $21 at Piper Sandler
- BofA says Hims’ semaglutide compounding opportunity may be shorter than expected